BMD measurement in a male with osteopenia/osteoporosis or low trauma fracture can be repeated in 1–2 years after testosterone replacement therapy is initiated (2,79). Current American Cancer Society guidelines suggest prostate cancer screening on an annual basis for any male over 50 years, for African American males over 45 years, and for higher risk males over 40 years (multiple first-degree relatives affected at an early age) (90). As a result of the concerns about prostate cancer it is important to monitor PSA levels and perform a DRE regularly during the course of treatment. Table 11 shows the principal monitoring requirements for testosterone therapy as specified by the Endocrine Society (2). Once testosterone replacement therapy has started, patients need to be carefully monitored. have been undertaken on the relationship between more general aggressive behavior, and feelings, and testosterone. This increases the reproductive fitness of the parents because their offspring are more likely to survive and reproduce.|Primary hypogonadism can result from testicular injury, tumour, or infection; genetic defects affecting testicular development (e.g. Klinefelter syndrome), as well as chemotherapy, radiation treatment or alcohol abuse (3,16). In this review, hypogonadism will be used as a general term to refer to any state characterised by low blood testosterone levels. A key consideration for any physician is to understand the clinical significance of low testosterone levels and how hypogonadal men are likely to benefit from testosterone replacement therapy. These are efficacious in establishing eugonadal testosterone levels in the blood and relieving symptoms.|In general, however, the term mixed hypogonadism is not used in clinical practice in the US and is considered part of secondary hypogonadism. This is found in men with sickle-cell disease, thalassemia, alcoholism, glucocorticoid treatment, and in older men (2). Patients with secondary hypogonadism can have their fertility restored by suitable hormonal stimulation, whereas those with primary hypogonadism resulting from testicular failure cannot.|Male hypogonadism is a clinical syndrome which comprises of symptoms with or without signs and biochemical evidence of testosterone deficiency. But hormone replacement therapy helps improve sex drive, symptoms of depression and energy levels. Most males with symptoms of low testosterone don’t have a problem with their pituitary glands or testicles. Providers call it male hypogonadism when you have symptoms along with these low levels. There is evidence, however, that testosterone will stimulate the growth of existing prostatic cancers and, of course, existing prostate cancer is contraindicated for testosterone therapy (4). Prostate volume does, however, increase during testosterone therapy usually in the first 6 months, but this is usually to the normal volume seen in eugonadal men.|Those low levels cause decreased testosterone and sperm production. Conditions that affect how your hypothalamus and/or pituitary gland work cause secondary hypogonadism. A problem with your pituitary gland or hypothalamus causes secondary hypogonadism. Any issue with your testicles, hypothalamus or pituitary gland can cause low testosterone. Sexual symptoms of low testosterone are the most specific.|Studies have found higher pre-natal testosterone or lower digit ratio to be correlated with higher aggression. Testosterone and other androgens have evolved to motivate men to pursue competition, even when doing so leads to risk. The second theory is similar and known as "evolutionary neuroandrogenic (ENA) theory of male aggression". Studies conducted have found direct correlation between testosterone and dominance, especially among the most violent criminals in prison who had the highest testosterone.|In the late-onset hypogonadal male, the addition of testosterone (even to return levels to a "normal" range) was hypothesized by extrapolation to increase prostatic size and thus worsened of LUTS secondary to BOO. While Favilla et al.15 were able to demonstrate an association between LUTS and serum levels of total testosterone in the study of 122 men with symptomatic BPH, they did not find a similar association with BPH/BPE and testosterone. However, Marks et al.14 recently disputed this concept when finding no evidence of increased intra-prostatic DHT with testosterone replacement therapy (TRT) in a small, randomized control trial (RCT). Urologists have known of testosterone's importance in prostate development and pathology for some time, but only more recently have we begun to better understand its effects on lower urinary tract symptoms (LUTS); and more importantly, that these symptoms are not always entirely due to bladder outlet obstruction (BOO). Surprisingly, numerous retrospective or small, randomized trials have pointed to a possible improvement in male lower urinary tract symptoms (LUTS) in patients treated with testosterone. The use of testosterone to treat the symptoms of late-onset hypogonadal men has increased recently due to patient and physician awareness.} Whether you're deep in a fertility journey, investigating unexplained symptoms, or simply reviewing routine bloodwork, an elevated LH level demands attention. Digital rectal examination may detect prostate abnormalities that can be present even in men with normal PSA values. Baseline and, at least, annually glyco-metabolic profile evaluation may be a reasonable consideration, particularly in the management of functional hypogonadism. Testosterone Trials were designed to maintain the serum testosterone concentration within the normal range for young men ( ng/dL or 9.6-30nmol/L) . In cases of elevated haematocrit without comorbidities, acute CV or venous thromboembolism events, management can include reducing the testosterone dose, switching to a different formulation, or - if haematocrit is markedly high - performing venesection (500mL), repeated if necessary. Testosterone therapy is contraindicated in men with severe chronic cardiac failure because fluid retention may lead to exacerbation of the condition. They release testosterone slowly, allowing for absorption through the gum and cheek surfaces. These are adhesive tablets containing testosterone that are applied to the gum just above the incisor teeth. An issue with gels is that testosterone can be transferred from the patient to his partner or to children after skin contact. Similarly, data derived from TTrials and the T4DM studies confirmed that testosterone therapy increased bone mineral density in ageing men with hypogonadism 102,124. One of the striking things about a study published in 2007 was that physicians’ number one fear about initiating testosterone therapy was their perception that it increases the risk of prostate cancer. A recent study showed that supervised diet and exercise increased testosterone levels in hypogonadal men with metabolic syndrome and newly diagnosed type 2 diabetes. In accordance with sperm competition theory, testosterone levels are shown to increase as a response to previously neutral stimuli when conditioned to become sexual in male rats. In humans, testosterone plays a key role in the development of male reproductive tissues such as testicles and prostate, as well as promoting secondary sexual characteristics such as increased muscle and bone mass, and the growth of body hair. Liu et al.12 demonstrated that in a group of older males (mean age 59.8 years) that there was not a significant correlation of serum testosterone levels (total, free or bioavailable) with either prostate volume or International Prostate Symptom Score (IPSS). Placebo-controlled RCTs of testosterone therapy in T2DM have demonstrated improved sexual desire and satisfaction, but not erectile function (EF) 30,39. High-density lipoprotein (HDL)-cholesterol may decrease, remain unchanged or increase with testosterone therapy. Several randomised controlled trials (RCTs) have demonstrated that testosterone therapy may improve insulin resistance and hyperglycaemia and lower total and low-density protein (LDL)-cholesterol 29-34. A compensated or subclinical form of hypogonadism, characterised by normal testosterone serum levels and elevated luteinising hormone (LH) production, has also been reported ; the clinical significance of this condition is unclear 18-21. Combined therapy with Continuous Positive Airway Pressure (CPAP) and testosterone gel was more effective than CPAP alone in the treatment of obstructive sleep apnoea . In most cases, discontinuation of testosterone therapy is not required.There is no evidence that testosterone therapy can result in onset or worsening of sleep apnoea. A meta-analysis of RCTs of testosterone therapy reported that venous thromboembolism was frequently related to underlying undiagnosed thrombophilia-hypofibrinolysis disorders . Any elevation above the normal range for haematocrit usually becomes evident between three and 12 months after testosterone therapy initiation. An interesting observation is that untreated hypogonadism increased the re-admission and mortality rate in men with heart failure .
